AviadoBio opens fourth ASPIRE-FTD cohort as AVB-101 regains full development rights and secures fresh backing from leading dementia foundations

AviadoBio, the London-based gene therapy company developing treatments for neurodegenerative diseases, has opened enrollment for the fourth dose-escalation cohort in its Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations. The announcement, made on 31 March 2026, comes alongside two structurally significant developments: AviadoBio has regained full worldwide rights to AVB-101 following the lapse of Astellas Pharma’s exclusive option agreement, and the company has secured a strategic investment from The Alzheimer’s Drug Discovery Foundation and The Association for Frontotemporal Degeneration through their Treat FTD Fund. Taken together, the three announcements represent a recalibration of the program from a partnered asset toward an independently controlled development stage, with external validation from patient advocacy-aligned capital.

Why AviadoBio’s intrathalamic delivery approach for FTD-GRN is clinically and mechanistically distinct from competing gene therapy programs

The defining characteristic of AVB-101 is not the gene it carries but where and how it is delivered. Across the FTD-GRN treatment landscape, the central challenge has never been identifying the biological target. Progranulin haploinsufficiency as a disease driver has been understood for over a decade, and the therapeutic logic of restoring GRN expression is shared by Passage Bio’s PBFT02, Prevail Therapeutics’ PR006 (now under Eli Lilly), and Denali Therapeutics’ TAK-594 in partnership with Takeda. What differs, and what ultimately may determine clinical outcomes, is the method of central nervous system access.

AVB-101 uses a stereotactic neurosurgical procedure to deliver the therapy directly into the thalamus, exploiting that structure’s extensive axonal connections to the frontal and temporal cortex, the regions most implicated in FTD pathology. By delivering the vector intraparenchymally to a hub structure rather than relying on intracisternal, intrathecal, or intravenous administration, AviadoBio is attempting to achieve targeted cortical biodistribution while keeping systemic vector exposure low and avoiding the need for immunosuppression. Passage Bio’s PBFT02, administered via intra-cisterna magna injection into cerebrospinal fluid, and Prevail’s PR006, also delivered intracisternally, differ in that the vector must rely on CSF circulation and parenchymal diffusion to reach relevant brain regions.

The intrathalamic approach carries its own execution risks. The procedure requires specialist neurosurgical infrastructure, limiting the number of centres capable of administering treatment and introducing logistical constraints on trial scaling and eventual commercial rollout. AviadoBio currently operates 20 active trial sites across the United States, United Kingdom, Canada, Belgium, Italy, the Netherlands, Poland, Spain, and Sweden. Achieving that footprint with a neurosurgically dependent protocol is a meaningful operational accomplishment, and the absence of serious adverse events across 12 treated patients in three completed cohorts provides early comfort on the safety profile.

What do the ASPIRE-FTD biomarker results released so far actually tell investors and clinical researchers about AVB-101’s prospects?

AviadoBio has disclosed dose-dependent elevations in cerebrospinal fluid progranulin across the first three cohorts, without reporting specific numerical values in this release. The dose-response relationship is the expected and necessary proof of target engagement for a gene supplementation therapy: it confirms that the vector is transducing relevant cells and producing functional protein. The absence of serious adverse events related to AVB-101 and the elimination of prophylactic or reactive immunosuppression represent operationally important findings, since immunogenicity responses to AAV vectors have complicated other CNS gene therapy programs.

However, the critical outstanding question is whether progranulin elevation translates to clinical benefit, a question that the broader FTD field is grappling with following the failure of latozinemab in Alector’s Phase 3 INFRONT-3 trial in October 2025. Latozinemab, the most advanced FTD-GRN therapy in the field and developed in collaboration with GSK, successfully raised plasma progranulin levels but failed to slow clinical progression on the CDR plus NACC FTLD-SB co-primary endpoint, with no treatment-related effects detected across secondary biomarker and imaging measures. Alector subsequently discontinued the open-label extension and cut nearly half its workforce.

The latozinemab failure does not invalidate the progranulin hypothesis for gene therapy programs, for a fundamental mechanistic reason. Latozinemab acts peripherally to block the sortilin receptor that degrades progranulin, elevating plasma rather than brain progranulin levels. Gene therapy approaches such as AVB-101 act intracellularly and intraparenchymally, directly inserting functional GRN copies into neurons in the most affected regions. The open question is whether restoring CNS-native progranulin production from within the relevant cell populations produces a meaningfully different outcome. AviadoBio’s decision to target CSF progranulin as the primary biomarker, rather than plasma progranulin, reflects this mechanistic distinction and positions the program more defensibly against the INFRONT-3 precedent.

How does AviadoBio regaining full rights to AVB-101 from Astellas affect the program’s capital structure and partnership optionality going forward?

Astellas entered into an exclusive option and license agreement with AviadoBio in October 2024, giving it the right to acquire worldwide commercialisation rights to AVB-101 in FTD-GRN and other indications. That option has now lapsed without being exercised, returning full global rights to AviadoBio. Astellas retains a minority shareholding position in the company but has no further obligations or entitlements with respect to the program.

The reversion is a double-edged development. On the positive side, it removes the dependency on a single major pharmaceutical partner for future commercialisation and eliminates any milestone or royalty overhang that might have complicated future licensing discussions. AviadoBio retains full economic upside across all geographies and indications. The practical constraint is that the company must fund continued clinical development from its own balance sheet and investor relationships, without the backstop of a large-pharma counterparty committed to downstream commercialisation.

The timing of the Treat FTD Fund investment from The Alzheimer’s Drug Discovery Foundation and The Association for Frontotemporal Degeneration is therefore strategically useful, providing external credibility and non-dilutive or selectively structured capital at a moment when the partnership landscape has been reset. The Treat FTD Fund, established in 2016, has a track record of investing in novel FTD clinical programs, and its participation serves as a signal of patient advocacy community confidence in AVB-101’s scientific rationale. That said, advocacy-linked capital is unlikely to cover the full cost of running a Phase 1/2 study across 20 sites in nine countries, meaning AviadoBio will likely need to secure additional institutional or strategic financing as the program advances toward data readouts.

What is the competitive and market context for a gene therapy addressing FTD-GRN, and how large is the opportunity AviadoBio is pursuing?

Frontotemporal dementia with GRN mutations affects approximately 11,000 people across the United States and the five major European markets, with roughly 2,200 new cases diagnosed annually. It is a leading cause of dementia in people under 65, typically presenting between the ages of 45 and 68, and currently has no approved disease-modifying treatments. The combination of a known genetic driver, measurable protein biomarker, and a patient population diagnosed at a relatively young and active life stage makes it a commercially plausible target for premium-priced gene therapy, despite the limited patient numbers.

The competitive field remains active despite the latozinemab setback. Passage Bio is advancing PBFT02, an AAV1-based gene therapy delivered via intra-cisterna magna injection, which has demonstrated robust CSF progranulin increases in early cohorts and is targeting further data readouts in 2026. Prevail Therapeutics, now a subsidiary of Eli Lilly, continues enrolling in the PROCLAIM trial of PR006, with interim Phase 1/2 results published in Nature Medicine in 2024 confirming CSF progranulin elevation and an acceptable early safety profile. Denali Therapeutics and Takeda are progressing TAK-594, a recombinant progranulin replacement that uses a blood-brain barrier crossing transport vehicle technology, in an IV-administered format that, if successful, would be far more scalable than surgical gene therapy delivery.

AVB-101’s clinical positioning therefore depends on demonstrating that the intrathalamic delivery approach generates superior or more durable cortical progranulin restoration compared with CSF-based gene therapy routes, while maintaining a procedural safety record that justifies the surgical burden. The planned data presentations at the Alzheimer’s Association International Conference in July 2026 and the International Society for Frontotemporal Dementias meeting in October 2026 will be closely watched for any indication of effect on functional or neurodegenerative biomarkers beyond target engagement.

What are the key execution risks AviadoBio must navigate between now and the planned data presentations in the second half of 2026?

Trial execution at 20 sites across nine countries for a surgical gene therapy involves a category of complexity that exceeds standard Phase 1/2 drug infusion studies. Each administration requires specialist neurosurgeons, MRI guidance infrastructure, real-time monitoring capability, and an expert neurosurgical centre designation. Patient eligibility in FTD-GRN is inherently constrained by diagnostic delays and historically low rates of genetic testing in the FTD population, a known recruitment challenge across the entire FTD-GRN therapeutic space. AviadoBio’s five-country reach for the first 12 patients, spanning three continents, suggests the site network has matured, but sustaining recruitment velocity into a fourth cohort requires the referral pipeline to scale in parallel.

The capital question is non-trivial. With Astellas having declined to exercise its option, AviadoBio’s runway depends on existing investors and incoming capital from sources including the Treat FTD Fund. The company’s pipeline includes an AAV optogenetic therapy for retinal dystrophies expanding into geographic atrophy and an Alzheimer’s disease program built around its vMiX RNA silencing platform, meaning R&D capital allocation decisions across multiple programs will compete for the same resources. Gene therapy clinical development at this scale is expensive, and the absence of a committed large-pharma development partner is a material consideration for investors evaluating the company.

The regulatory landscape also bears watching. AVB-101 holds FDA Fast Track designation and orphan designation from both the FDA and the European Commission, providing procedural advantages but no guarantee of accelerated timelines. The FDA’s engagement with the FTD-GRN biomarker framework, demonstrated through its co-primary endpoint amendment in the INFRONT-3 trial, suggests the agency is actively calibrating its evidentiary standards as the field develops. Gene therapy programs with neurosurgical delivery requirements face additional scrutiny around procedural risk standardisation and reproducibility across sites.

Key takeaways: What the AviadoBio AVB-101 Phase 1/2 fourth cohort opening means for the FTD-GRN gene therapy field and competitive landscape

• AviadoBio has initiated its fourth ASPIRE-FTD dose-escalation cohort, having dosed 12 patients across three completed cohorts at 20 sites in nine countries with no serious AVB-101-related adverse events and dose-dependent CSF progranulin elevation.
• Astellas Pharma’s exclusive option on AVB-101 has lapsed unexercised, returning full worldwide rights to AviadoBio across all geographies and indications, while Astellas retains a minority equity stake.
• The Treat FTD Fund, backed by The Alzheimer’s Drug Discovery Foundation and The Association for Frontotemporal Degeneration, has made a strategic investment in the program, providing patient advocacy validation and supplementary capital.
• The intrathalamic delivery route, which bypasses the blood-brain barrier via direct parenchymal injection to a neuroanatomical hub, is mechanistically distinct from CSF-based gene therapy delivery used by Passage Bio and Prevail Therapeutics.
• The October 2025 failure of latozinemab in Alector’s Phase 3 INFRONT-3 trial, which raised plasma but not CSF progranulin without clinical benefit, creates a cautionary precedent but does not directly invalidate intracellular CNS gene therapy approaches targeting CSF progranulin.
• Passage Bio’s PBFT02 and Prevail’s PR006 remain active competing gene therapy programs with their own 2026 data catalysts, creating a year in which comparative clinical signals across delivery modalities will sharpen.
• AviadoBio plans to present AVB-101 data at the Alzheimer’s Association International Conference in July 2026 and the International Society for Frontotemporal Dementias meeting in October 2026; functional and neurodegenerative biomarker data beyond target engagement will be the critical investor and clinical focus.
• The absence of a committed large-pharma development partner following the Astellas option lapse raises balance sheet and financing questions that the company will need to address as the program advances toward pivotal stage decision points.
• FTD-GRN remains a commercially viable rare disease target with approximately 11,000 prevalent patients in the US and EU5 and no approved disease-modifying treatment, supporting premium gene therapy pricing assumptions if efficacy is demonstrated.
• AVB-101’s FDA Fast Track and orphan designations provide procedural advantages, but the requirement for specialist neurosurgical infrastructure at every treatment site is a structural commercial constraint that AviadoBio will need to address in any regulatory and market access strategy.